WeVote
Log In

Bill

Bill

HB 2462

DILLON’S LAW

104th Regular Session Introduced by Christopher Belt and 13 co-sponsors

Expands stocking and use of undesignated epinephrine injectors to trained non-medical personnel, with required training and limited liability for good-faith administration.

Public Act . . . . . . . . . 104-0229
0
WeVote Research Nonpartisan
Bill Summary · HB 2462

HB 2462 — "Dillon’s Law" (Public Act 104‑0229)

Enacted: Public Act 104‑0229
Governor approved: August 15, 2025 — Effective date: January 1, 2026

Purpose

Amends the Epinephrine Injector Act (410 ILCS 27) and the Good Samaritan Act (745 ILCS 49) to expand where undesignated epinephrine injectors may be stocked and used, define and authorize trained non‑medical personnel to provide or administer epinephrine in suspected anaphylaxis, require training/certification, and limit civil liability for those acting in good faith.

Key provisions

  • Definitions: adds and clarifies terms including “authorized entity,” “authorized individual” (sometimes framed as “authorized youth sports individual”), “epinephrine delivery system,” and “undesignated epinephrine injector.”
  • Prescriptions and stocking:
    • Health care practitioners may prescribe epinephrine injectors in the name of an authorized entity or authorized individual; such prescriptions are valid for 2 years.
    • Authorized entities/individuals may acquire and stock undesignated epinephrine injectors and must store them accessible for emergency use in accordance with manufacturer instructions.
    • A health care provider employed by or under contract with the Department of Public Health may issue a statewide standing order for dispensing epinephrine delivery systems for trained authorized individuals or employees/agents who completed required training.
  • Training and certification:
    • Persons must complete an anaphylaxis training program (conducted by nationally recognized organizations experienced in layperson emergency training) before providing/ administering injectors.
    • Training must include recognition of anaphylaxis, how to administer the device, and a competency test. Training is valid for 2 years; successful completers receive a certificate. The Department will approve/list training providers.
  • Costs: whichever entity initiates obtaining the undesignated injectors and training must pay associated costs.
  • Professional practice: use per the Act does not constitute practicing medicine or require licensure; no cap on quantity of injectors an entity may keep.
  • Liability and Good Samaritan protections:
    • Adds a liability limitation: authorized individuals acting in good faith to provide or administer epinephrine are shielded from civil liability, except for willful and wanton misconduct.
    • House amendment narrows that limitation to cover only the act of providing/administration of the epinephrine delivery system (not other contemporaneous care).

Who is affected

  • Authorized entities: non‑school organizations where allergens may be present (e.g., youth sports leagues, recreation camps, colleges/universities, day care as defined by Dept. rule, restaurants, sports arenas, workplaces, transportation contractors).
  • Authorized individuals: employees, agents, or other persons who complete the required training and certification.
  • Health care practitioners and pharmacists who prescribe/dispense undesignated injectors.
  • Pharmacies/manufacturers and training providers (identified/approved by the Department).

Implementation / timeline & procedural notes

  • Department of Public Health will adopt rules, determine day care definitions, approve training programs and post provider links.
  • Prescriptions and training certificates are valid for 2 years.
  • Enacted and codified changes to 410 ILCS 27 (Epinephrine Injector Act) and adds Sec. 66 to 745 ILCS 49 (Good Samaritan Act).
  • Legislative history: passed both houses, enrolled, sent to Governor June 20, 2025; Governor approved Aug 15, 2025; effective Jan 1, 2026.

Potential impact and considerations

  • Likely to increase rapid access to life‑saving epinephrine in public and recreational settings by empowering trained non‑medical persons to provide or administer injectors.
  • Creates uniform training and certification expectations and extends civil liability protection, potentially increasing voluntary stocking and use.
  • Costs of procuring injectors and training fall to entities that initiate the program — a possible barrier for smaller organizations unless subsidized.
  • The liability carve‑out is limited (excluding willful/wanton misconduct and, by amendment, limited to the act of providing/administering epinephrine), which balances protection with accountability.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.